Oral GLP-1 Reduces Weight & HbA1c in Obesity/Type 2 Diabetes
Here’s a breakdown of the key information from the provided text:
Main Topic: A new drug for obesity is nearing potential approval and will require careful post-market monitoring,notably for liver effects.
Key Points:
* Approval Pending: The drug is awaiting approval from a regulatory agency.
* Post-Marketing Surveillance: Even though clinical trials showed no significant liver issues, the drug’s safety will be closely monitored after it’s released to the general public (“real-world population”). This is because people taking the drug in everyday life may differ from those in the controlled clinical trial setting.
* Liver Effects focus: The primary safety concern is potential liver effects, and liver enzyme levels will be carefully watched.
* Clinical trial Results: The clinical trials were thorough in assessing liver safety,and no concerning signals were detected.
source Information:
* Presentation: The information was presented at ObesityWeek (November 4-7, 2025, Atlanta) as part of the ATTAIN corporate oral session.
* Citation: Shukla A,et al. ATTAIN corporate orals session.
* funding: The study was funded by Eli Lilly.
* disclosures: Several individuals involved in the study (Alfaris,Horn,Ryan) have financial relationships with various pharmaceutical companies,including Eli Lilly,which funded the study. These relationships include consulting, speaking engagements, research support, and stock ownership.
Additional Information:
* Healio AI Promotion: The article includes a promotional section for Healio AI, a tool that provides access to medical information from sources like PubMed, guidelines, and Healio’s news coverage.
* Publisher: Published by Endocrine Today.